GSK extends offer for Human Genome Sciences
GlaxoSmithKline Plc has again extended its $13 per share cash offer for Human Genome Sciences Inc- this time to a date after management will have completed a review of other strategic options. GSK’s offer to shareholders is now set to expire on 20 July.